LOCALLY ADVANCED SOLID TUMORS
Clinical trials for LOCALLY ADVANCED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMORS trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug combo enters first human tests
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. Ab…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC